Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Intercept Pharmaceuticals, Inc. $460 Million Convertible Senior Notes Offering
Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with an SEC…
Magellan Pharmacy Services, Inc. $200 Million Term Loan Facility
Davis Polk advised the administrative agent in connection with a $200 million term loan facility (the “Credit Facility”) for…
McKesson formation of a new company with Change Healthcare Holdings
Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will…
Medtronic Acquires HeartWare International
Davis Polk is advising Perella Weinberg as financial adviser to HeartWare International, Inc. in connection with its $1.1…
Universal American Corp. $115 Million Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an…
Global Blood Therapeutics, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $120 million follow-on offering of common stock of…
Spark Therapeutics Follow-On Offering
Davis Polk advised the representative of the underwriters in connection with the $181 million public offering of 4,025,000…
Nevro Corp. $172.5 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Nevro…
The Medicines Company $402.5 Million Convertible Senior Notes Offering
Davis Polk advised the joint bookrunners in connection with a Rule 144A offering by The Medicines Company of $402.5 million…
Davis Polk Advises Aetna on Its $13 Billion Senior Notes Offering
Davis Polk advised Aetna Inc. on its SEC-registered notes offering of $13 billion aggregate principal amount of senior notes…